Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-06
DOI
10.1002/cam4.6628
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer
- (2023) Ryota Tanaka et al. PLoS One
- Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
- (2023) Chengpei Zhu et al. Frontiers in Immunology
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2023) Robin Kate Kelley et al. LANCET
- Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
- (2023) Xin Qiu et al. Human Vaccines & Immunotherapeutics
- Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
- (2022) Davide Ciardiello et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
- (2022) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers
- (2022) Roberta Giorgione et al. Immunotherapy
- Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2022) Qi Jiang et al. Frontiers in Immunology
- Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
- (2022) Sandra Kang et al. Cancers
- The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
- (2022) Daniel R. Principe et al. PHARMACOLOGY & THERAPEUTICS
- Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2022) Liwei Ni et al. Frontiers in Nutrition
- 65P A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers
- (2022) H. Li ANNALS OF ONCOLOGY
- Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer
- (2022) Dae Won Kim et al. EUROPEAN JOURNAL OF CANCER
- Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
- (2022) Zhenyun Yang et al. Journal of Inflammation Research
- Blood tests predict the therapeutic prognosis of anti‐PD‐1 in advanced biliary tract cancer
- (2021) Fei Du et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial
- (2021) Xinni Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy
- (2021) Jie Mei et al. Journal of Inflammation Research
- Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012
- (2020) Andrea A. Florio et al. CANCER
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Lymphocyte‐C‐reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study
- (2020) Liang‐He Lu et al. LIVER INTERNATIONAL
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- (2019) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Current standards and future perspectives in adjuvant treatment for biliary tract cancers
- (2019) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
- (2018) Fan Feng et al. BMC GASTROENTEROLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
- (2017) Francesca R. Bertani et al. Scientific Reports
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- (2013) B Goeppert et al. BRITISH JOURNAL OF CANCER
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started